MCMarcela Contreras

Marcela Contreras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcela Contreras has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vaccination Coverage Quality Indicators (VCQI): a flexible open-source tool for survey data analysis.

    by Dale A Rhoda, Caitlin B Clary, Mary Kay Trimner, Mia Yu, Jennifer Brustrom, Marcela Contreras, M Carolina Danovaro-Holliday, Martha Velandia-González

    The World Health Organization (WHO) and Pan American Health Organization (PAHO) make statistical software scripts freely available to conduct standardized analysis of vaccination coverage surveys. The software and accompanying documentation are named the Vaccination Coverage Quality Indicators (VCQI). The software examines data from child vaccination records and caregiver recall to calculate indicators of vaccination access, coverage, continuity, and quality. VCQI produces output tables and figures that may be copied directly into reports and presentations, as well as survey response data sets augmented with child-level outcome indicator variables calculated according to WHO guidance. It can analyze data from routine immunization surveys, post-campaign coverage surveys, and maternal tetanus coverage surveys. VCQI may be used for either the primary analysis of data from new surveys or secondary analysis of earlier surveys. It can analyze data from USAID Demographic and Health Surveys, UNICEF Multiple-Indicator Cluster Surveys, or WHO Expanded Programme on Immunization surveys. Future versions of VCQI may be extended to analyze data from electronic immunization registries. VCQI has been available as a set of Stata scripts since 2015, and as of 2025, the core routine immunization indicators are also available as a new R package named vcqiR. To publicize VCQI's features and capabilities and to celebrate the milestone of R package availability, the authors share this special report to describe the VCQI vision and design, discuss analyses and insights available from it, and map our vision of what the future may hold for flexible standardized analysis of vaccination coverage data.

  • Open Access

    Global COVID-19 vaccination uptake across the emergency and early post-emergency periods, 2021-2024

    by Donald J. Brooks, Ashley Germann, Laura Craw, Laure Dumolard, Yoann Nedelec, Ayşe Açma, Craig Schultz, Franck Mboussou, Ajiri Atagbaza, Reena H. Doshi, et al.

    COVID-19 vaccination helped change the course of the pandemic and remains critical for protecting high-risk groups. We analyzed data submitted to WHO to describe COVID-19 vaccination coverage during the emergency period from 2021-2023 and annual uptake in 2024, the first post-emergency calendar year after the Public Health Emergency of International Concern designation was lifted. By end-2023, global complete primary series coverage reached 65% in the total population, 82% among older adults, and 91% among health and care workers (HCWs), across reporting countries. Booster coverage was lower, at 33%, 60%, and 69%, respectively. Across indicators, disparities by country income group and region emerged early and persisted through 2024. In 2024, vaccination of older adults and HCWs was limited and heterogeneous. These findings underscore the need for stronger, sustainably financed adult immunization platforms and associated monitoring systems to enhance life-course vaccination benefits and to support future outbreak, epidemic, and pandemic responses.

  • Open Access

    Correction: Loayza et al. Monitoring the Performance of National Immunization Programs: Innovative Methodology and Tool for Countries’ Self-Assessment. Vaccines 2026, 14, 258

    by Sergio Loayza, Bertha Capistrán, Marcela Contreras, Martha Velandia, Daniel Salas

    The authors would like to make the following correction to this published paper


  • Open Access

    Monitoring the Performance of National Immunization Programs: Innovative Methodology and Tool for Countries’ Self-Assessment

    by Sergio Loayza, Bertha Capistrán, Marcela Contreras, Martha Velandia, Daniel Salas

    Background/Objectives: In the context of its policy of “Reinvigorating Immunization as a Public Good for Universal Health,” the Pan American Health Organization (PAHO) developed a methodology and tool (MD-PAI) to help Member States of the Americas monitor and assess the performance of their national Expanded Program on Immunization (EPI) for each of the 13 technical components that make up the program. Methods: The MD-PAI was developed in several stages, including review of existing national EPI evaluation methodologies, selection and prioritization of questions for each of the 13 EPI components, piloting of the methodology, final calibration to ensure validity, completeness, reliability, standardization, usefulness, and usability across components and across countries, and publication in the four official languages of the PAHO. Results: The implementation of the MD-PAI enables countries to collect data, document lessons learned, develop action plans to close the most urgent gaps in the short and medium term and enforce the management of the EPI as part of the continuous improvement process. Since its introduction in 2023, fourteen countries in the Americas implemented the MD-PAI, using the results for their short- and medium-term planning and budgeting. Of the 13 components of the EPI, those that have performed best are political priority and planning and programming, while social communication is the component that reported the greatest number of gaps across countries. Conclusions: The PAHO has developed a methodology and tool to help countries to assess their EPIs to identify good practices, gaps and challenges, and develop an action plan to strengthen their programs. However, the impact of vaccination coverages and the epidemiology of vaccine-preventable diseases could take time.


  • Open Access

    Global Status of Adult Immunization Post COVID-19 Pandemic

    by Alba Vilajeliu, Victor Vega, Randie Gibson, Francisco Nogareda, Xiaojun Wang, Donald J. Brooks, Charles Shey Wiysonge, Osman Niyazi Cakmak, Osama Mere, Melanie Marti, et al.

    Background/Objective: Historically, immunization programs have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. The objective of this manuscript is to provide a global overview of adult immunization policies post COVID-19 pandemic. Methods: We summarized WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations by adult group and analyzed the data reported in 2024 (2023) by WHO Member States (MS) via the WHO/UNICEF electronic Joint Reporting Form on Immunization (eJRF) on national immunization schedules, and from other sources by WHO region and income group. Results: WHO policy recommendations exist for most of the licensed vaccines targeting adults; however, the inclusion in national immunization schedules is higher in high-income (HICs) and middle-income (MICs) countries. For pregnant women, 90% of MS reported vaccination against COVID-19 (65% in low-income countries [LICs]), 63% against tetanus-containing vaccines (73% in LICs), 57% against influenza (4% in LICs), and 21% against pertussis-containing vaccines (all MICs and HICs). For health workers, 91% against COVID-19 (92% in LICs), 59% against influenza (4% in LICs), and 25% against hepatitis B (10% in LICs). For adults with chronic diseases, COVID-19 vaccination data were not available, 58% against influenza, and 23% against pneumococcal disease. For older adults, more than 90% of MS across all income groups reported COVID-19 vaccination, 59% against influenza (8% of LICs versus 89% of HICs), 17% against pneumococcal, and 7% against herpes zoster (HZ). Conclusion: The disparities in adult immunization policies across income groups highlight the need to improve access and strengthen vaccination efforts. A life course approach is essential to maximize the full potential of immunization across all ages.


  • Open Access

    Global Status of Adult Immunization Post COVID-19 Pandemic

    by Alba Vilajeliu, Victor Vega, Randie Gibson, Francisco Nogareda, Xiaojun Wang, Donald Brooks, Charles Shey Wiysonge, Osman Niyazi Cakmak, Osama Mere, Melanie Marti, et al.

    Background: Historically, immunization programmes have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. This manuscript provides a global overview of adult immunization post COVID-19 pandemic. Methods: We summarized WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations by adult group and analyzed the data reported in 2024 (2023) by WHO Member States (MS) via the WHO/UNICEF electronic Joint Reporting Form on Immunization (eJRF) on national immunization schedules, and from other sources by WHO region and income group. Results: WHO policy recommendations exist for most of the licensed vaccines targeting adults; however, the inclusion in national immunization schedules is higher in high-income (HICs) and middle-income (MICs) countries. For pregnant women, 90% of MS reported vaccination against COVID-19 (65% in low-income countries [LICs]), 63% against tetanus-containing vaccines (73% in LICs), 57% against influenza (4% in LICs), and 21% against pertussis-containing vaccines (all MICs and HICs). For health workers, 91% against COVID-19 (92% in LICs), 59% against influenza (4% in LICs), and 25% against hepatitis B (10% in LICs). For adults with chronic diseases, COVID-19 vaccination data were not available, 58% against influenza, and 23% against pneumococcal disease. For older adults, more than 90% of MS across all income groups reported COVID-19 vaccination, 59% against influenza (8% of LICs versus 89% of HICs), 17% against pneumococcal, and 7% against herpes zoster. Conclusion: The disparities in adult immunization policies across income groups highlight the need to improve access and strengthen vaccination efforts. A life course approach is essential to maximize the full potential of immunization across all ages.


  • Open Access

    Vaccine Certificates Must Go Digital: An Urgent Call for Better Public Health Outcomes

    by Jarbas Barbosa da Silva Júnior, Sebastian Garcia-Saiso, Myrna Marti, Daniel Salas, Marcela Contreras, Martha Velandia-Gonzalez, Daniel Luna, Jennifer Nelson, James Fitzgerald, Ernesto Bascolo, et al.

    From our roles within international public health organizations, we have collectively witnessed the global challenges presented by outdated health information systems, platforms, and applications. The COVID-19 pandemic has clearly exposed the limitations of our current paper-based vaccine certification methods and highlighted the deficiencies of outdated technological platforms that lack interoperability standards, a situation that underscores the critical need for a digital transformation in how we manage and verify immunization records. Digital vaccination certificates are understood to be secure, electronically stored, and easily accessible records that provide verifiable proof of a person’s immunization status. The Pan American Health Organization (PAHO) envisions leveraging digital technologies to strengthen health systems, enhance data-driven decision-making, and improve health outcomes. The organization’s vision emphasizes the integration of innovative technologies to build resilient and responsive health systems capable of addressing modern public health challenges. In an era of unprecedented technological advancement, our continued reliance on paper-based vaccine certificates is not just anachronistic—it is a significant liability for global public health that impacts the efficiency and effectiveness of our health systems on multiple fronts, limiting our ability to respond to public health crises effectively. With the strategic guidance from its Member States, PAHO has agreed to move toward the digital transformation of the health sector across the entire continent with an initiative that aims to improve health outcomes, ensure equitable access to health services, and enhance the overall efficiency of health systems in the Americas. The roadmap for this digital transformation outlines strategic actions and goals to achieve a connected, efficient, and resilient health sector.


  • Open Access

    The Impact of the Coronavirus Pandemic on Vaccination Coverage in Latin America and the Caribbean

    by Ignacio E. Castro-Aguirre, Dan Alvarez, Marcela Contreras, Silas P. Trumbo, Oscar J. Mujica, Daniel Salas Peraza, Martha Velandia-González

    Background: Routine vaccination coverage in Latin America and the Caribbean declined prior to and during the coronavirus pandemic. We assessed the pandemic’s impact on national coverage levels and analyzed whether financial and inequality indicators, immunization policies, and pandemic policies were associated with changes in national and regional coverage levels. Methodology: We compared first- and third-dose coverage of diphtheria–pertussis–tetanus-containing vaccine (DTPcv) with predicted coverages using time series forecast modeling for 39 LAC countries and territories. Data were from the PAHO/WHO/UNICEF Joint Reporting Form. A secondary analysis of factors hypothesized to affect coverages during the pandemic was also performed. Results: In total, 31 of 39 countries and territories (79%) had greater-than-predicted declines in DTPcv1 and DTPcv3 coverage during the pandemic, with 9 and 12 of these, respectively, falling outside the 95% confidence interval. Within-country income inequality (i.e., Gini coefficient) was associated with significant declines in DTPcv1 coverage, and cross-country income inequality was associated with declines in DTPcv1 and DTPcv3 coverages. Observed absolute and relative inequality gaps in DTPcv1 and DTPcv3 coverage between extreme country quintiles of income inequality (i.e., Q1 vs. Q5) were accentuated in 2021, as compared with the 2019 observed and 2021 predicted values. We also observed a trend between school closures and greater-than-predicted declines in DTPcv3 coverage that approached statistical significance (p = 0.06). Conclusion: The pandemic exposed vaccination inequities in LAC and significantly impacted coverage levels in many countries. New strategies are needed to reattain high coverage levels.


  • Top Cited Papers
    Open Access

    HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019

    by Laia Bruni, Anna Saura-Lázaro, Alexandra Montoliu, Maria Brotons, Laia Alemany, Mamadou Saliou Diallo, Oya Zeren Afsar, D. Scott LaMontagne, Liudmila Mosina, Marcela Contreras, et al.


  • Open Access

    Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas

    by Alba Maria Ropero Álvarez, Silvia Pérez-Vilar, Carmelita Pacis-Tirso, Marcela Contreras, Nathalie El Omeiri, Cuauhtémoc Ruiz-Matus, Martha Velandia-González

    Over recent decades, the Region of the Americas has made significant progress towards hepatitis B elimination. We summarize the countries/territories’ efforts in introducing and implementing hepatitis B (HB) vaccination and in evaluating its impact on HB virus seroprevalence. We collected information about HB vaccination schedules, coverage estimates, and year of vaccine introduction from countries/territories reporting to the Pan American Health Organization/World Health Organization (PAHO/WHO) through the WHO/UNICEF Joint Reporting Form on Immunization. We obtained additional information regarding countries/territories vaccination recommendations and strategies through communications with Expanded Program on Immunization (EPI) managers and national immunization survey reports. We identified vaccine impact studies conducted and published in the Americas. As of October 2016, all 51 countries/territories have included infant HB vaccination in their official immunization schedule. Twenty countries, whose populations represent over 90% of the Region’s births, have included nationwide newborn HB vaccination. We estimated at 89% and 75%, the regional three-dose series and the birth dose HB vaccination coverage, respectively, for 2015. The impact evaluations of infant HB immunization programs in the Region have shown substantial reductions in HB surface antigen (HBsAg) seroprevalence. The achievements of vaccination programs in the Americas suggest that the elimination of perinatal and early childhood HB transmission could be feasible in the short-term. Moreover, the data gathered indicate that the Region may have already achieved the 2020 WHO goal for HB control.